Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII meeting

The FDA gathers Wednesday to hear what industry stakeholders and the public want included in the latest iteration of the Prescription Drug User Fee Act that sets the agency’s priorities for fiscal years 2028–2032.